Celularity (CELU) announced its research published in the May 29, 2025, issue of the peer-reviewed journal Regenerative Engineering and Translational Medicine, a leading open-access journal publishing cutting-edge advances in regenerative medicine. The full study titled “Tri-Layer Decellularized, Dehydrated Amniotic Membrane Supports Proliferation and Stemness of Limbal Stem Cells Derived from Pluripotent Stem Cells” demonstrates the potential of Celularity’s proprietary tri-layer decellularized, dehydrated human amniotic membrane as an innovative carrier for induced pluripotent stem cell-derived limbal stem cells in treating limbal stem cell deficiency and other ocular surface disorders. The research conducted in collaboration with Dr. Jessica M. Gluck’s team at North Carolina State University highlights DDHAM-3L’s ability to support the adhesion, proliferation, and stemness of iPSC-derived LSCs. Over a 7-day in vitro study, iPSC-LSCs seeded on DDHAM-3L formed confluent cell sheets, exhibited epithelial morphology, and demonstrated a higher proliferation rate compared to controls. Gene and protein expression analyses further confirmed the upregulation of markers associated with stemness, self-renewal, and corneal epithelial commitment, underscoring DDHAM-3L’s potential as an advanced biomaterial for ocular surface reconstruction.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELU:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue